PL1776387T3 - Angiogenne i immunologiczne zastosowania swoistych związków anty-CD160 możliwych do uzyskania z mAb CL1-R2 - Google Patents

Angiogenne i immunologiczne zastosowania swoistych związków anty-CD160 możliwych do uzyskania z mAb CL1-R2

Info

Publication number
PL1776387T3
PL1776387T3 PL05789182T PL05789182T PL1776387T3 PL 1776387 T3 PL1776387 T3 PL 1776387T3 PL 05789182 T PL05789182 T PL 05789182T PL 05789182 T PL05789182 T PL 05789182T PL 1776387 T3 PL1776387 T3 PL 1776387T3
Authority
PL
Poland
Prior art keywords
angiogenic
mab
specific compounds
compounds obtainable
applications
Prior art date
Application number
PL05789182T
Other languages
English (en)
Inventor
Armand Bensussan
Laurence Boumsell
Bouteiller Philippe Le
Original Assignee
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med filed Critical Inst Nat Sante Rech Med
Publication of PL1776387T3 publication Critical patent/PL1776387T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2836—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD106
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
PL05789182T 2004-08-09 2005-08-09 Angiogenne i immunologiczne zastosowania swoistych związków anty-CD160 możliwych do uzyskania z mAb CL1-R2 PL1776387T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04292015A EP1626059A1 (en) 2004-08-09 2004-08-09 Angiogenic and immunologic applications of anti-CD160 specific compounds obtainable from mAb CL1-R2
PCT/EP2005/009231 WO2006015886A1 (en) 2004-08-09 2005-08-09 Angiogenic and immunologic applications of anti-cd160 specific compounds obtainable from mab cl1-r2
EP05789182A EP1776387B1 (en) 2004-08-09 2005-08-09 Angiogenic and immunologic applications of anti-cd160 specific compounds obtainable from mab cl1-r2

Publications (1)

Publication Number Publication Date
PL1776387T3 true PL1776387T3 (pl) 2011-01-31

Family

ID=34931332

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05789182T PL1776387T3 (pl) 2004-08-09 2005-08-09 Angiogenne i immunologiczne zastosowania swoistych związków anty-CD160 możliwych do uzyskania z mAb CL1-R2

Country Status (10)

Country Link
US (4) US20090317401A1 (pl)
EP (2) EP1626059A1 (pl)
JP (1) JP5162239B2 (pl)
AT (1) ATE475674T1 (pl)
CA (1) CA2576627C (pl)
DE (1) DE602005022589D1 (pl)
DK (1) DK1776387T3 (pl)
ES (1) ES2349015T3 (pl)
PL (1) PL1776387T3 (pl)
WO (1) WO2006015886A1 (pl)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2507213C2 (ru) 2005-10-04 2014-02-20 Солидженикс, Инк., Новые пептиды для лечения и профилактики иммунопатологических заболеваний, включая лечение и профилактику инфекции посредством модулирования врожденного иммунитета
EP1880729A1 (en) * 2006-07-20 2008-01-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of soluble CD160 to suppress immunity
EP2210903A1 (en) * 2009-01-21 2010-07-28 Monoclonal Antibodies Therapeutics Anti-CD160 monoclonal antibodies and uses thereof
CN102892432A (zh) 2010-05-28 2013-01-23 国家医疗保健研究所 用于治疗基于新血管生成的眼部疾病的抗-cd160特异性抗体
US9982023B2 (en) * 2011-11-15 2018-05-29 Sanford-Burnham Medical Research Institute Compositions and methods for treating autoimmune and inflammatory disorders
CN110121508A (zh) 2016-10-25 2019-08-13 法国国家健康和医学研究院 与cd160跨膜同种型结合的单克隆抗体
FR3061716B1 (fr) * 2017-01-06 2019-05-17 Elsalys Biotech Nouveaux composes ciblant le cd160 humain
WO2020127377A1 (en) 2018-12-21 2020-06-25 Ose Immunotherapeutics Bifunctional anti-pd-1/il-7 molecule
WO2020165374A1 (en) 2019-02-14 2020-08-20 Ose Immunotherapeutics Bifunctional molecule comprising il-15ra
CN113613664B (zh) * 2019-03-01 2025-11-18 阿奇洛伊斯生物制药公司 在抗原特异性免疫细胞中调节cd160功能的方法及其用途
AU2020406083A1 (en) 2019-12-17 2022-06-16 Boehringer Ingelheim International Gmbh Bifunctional molecules comprising an IL-7 variant
WO2022013256A1 (en) 2020-07-15 2022-01-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of cd160 as a biomarker in acute myeloid leukemia
IL300314A (en) 2020-10-08 2023-04-01 Affimed Gmbh Coupling materials with triple specificity
GB202103706D0 (en) * 2021-03-17 2021-04-28 Ucl Business Ltd CD160 binding domain
EP4320156A1 (en) 2021-04-09 2024-02-14 Ose Immunotherapeutics Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains
EP4320155A1 (en) 2021-04-09 2024-02-14 Ose Immunotherapeutics New scaffold for bifunctional molecules with improved properties
IL308154A (en) 2021-07-30 2023-12-01 Affimed Gmbh Double structure antibodies
CN119137151A (zh) 2022-03-09 2024-12-13 阿德莱恩生物技术公司 抗cd160跨膜同种型抗体
WO2023222886A1 (en) 2022-05-20 2023-11-23 Depth Charge Ltd Antibody-cytokine fusion proteins
CN119907811A (zh) 2022-08-02 2025-04-29 Ose免疫疗法公司 针对cd28的多功能分子
KR20250068626A (ko) 2022-09-15 2025-05-16 아비디큐어 아이피 비.브이. Nk 세포 자극을 위한 다중특이적 항원 결합 단백질 및 이의 용도
WO2025191133A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Il-21 muteins, fusion proteins comprising the same and uses thereof
WO2025191136A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Muteins of 4-1bb ligand extracellular domain, fusion proteins comprising the same and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0714510B1 (en) * 1993-08-27 2002-06-19 Dana Farber Cancer Institute Natural killer cell-specific antigen and antibodies that identify the same
AU5253898A (en) * 1996-11-12 1998-06-03 Dana-Farber Cancer Institute Recombinant by55 and nucleic acids encoding same
AU783899B2 (en) * 1999-11-15 2005-12-22 Innate Pharma S.A.S. Novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells, and antibodies that identify the same
FR2828403B1 (fr) * 2001-08-07 2003-10-17 Abtech Utilisation de molecules solubles hla de classe 1 pour la preparation de compositions pharmaceutiques utiles pour inhiber l'angiogenese
EP1578366A4 (en) * 2002-10-09 2007-12-19 Tolerrx Inc MOLECULES PREFERABLY ASSOCIATED WITH EFFECTOR T CELLS OR REGULATORY T CELLS AND METHODS OF USE THEREOF

Also Published As

Publication number Publication date
US20140120110A1 (en) 2014-05-01
CA2576627A1 (en) 2006-02-16
DE602005022589D1 (de) 2010-09-09
EP1626059A1 (en) 2006-02-15
WO2006015886A1 (en) 2006-02-16
US20150004170A1 (en) 2015-01-01
ES2349015T3 (es) 2010-12-21
EP1776387A1 (en) 2007-04-25
DK1776387T3 (da) 2010-11-22
CA2576627C (en) 2014-02-18
US8444978B2 (en) 2013-05-21
JP2008517873A (ja) 2008-05-29
EP1776387B1 (en) 2010-07-28
US20120003224A1 (en) 2012-01-05
US20090317401A1 (en) 2009-12-24
JP5162239B2 (ja) 2013-03-13
ATE475674T1 (de) 2010-08-15

Similar Documents

Publication Publication Date Title
PL1776387T3 (pl) Angiogenne i immunologiczne zastosowania swoistych związków anty-CD160 możliwych do uzyskania z mAb CL1-R2
IL185754A0 (en) Novel anti-plgf antibody
WO2004029092A3 (fr) Anticorps pour adcc et induisant la production de cytokines.
EP1461081A4 (en) ANTI-CD45RB ANTIBODY FOR USE IN THE TREATMENT OF AUTOIMMUNE DISEASES AND TRANSPLANT ABLUSION
WO2007047112A3 (en) Anti-myostatin antibodies
WO2009135861A3 (en) Humanized antibodies against human interferon-alpha
TW200510459A (en) RG1 antibodies and uses thereof
HRP20181459T1 (hr) Humanizirani antagonisti anti-beta7 i njihove uporabe
AU2003215188A8 (en) Fusion proteins of humanized g250 specific antibodies and uses thereof
IL201889A (en) Medication for the treatment of vaccine-related disorders containing antibodies that specifically recognize the nk 1.1 antigen or cd56 antigen expressed by nk t cells
WO2007129895A3 (en) Deimmunized antagonistic anti-human cd40 monoclonal antibody from the ch5d12 antibody
MXPA05007853A (es) Antagonistas de il-1 beta humana.
EA200870050A1 (ru) Анти-il-17-антитела
MX355256B (es) Anticuerpos anti-il-17a/il-17f de reactividad cruzada y métodos de uso de los mismos.
MXPA03005273A (es) Anticuerpos producidos procarioticamente y sus usos.
WO2007044756A3 (en) Monoclonal antibodies recognizing human ccr8
EP2380592A3 (en) Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
MX2011009312A (es) Formulaciones de anticuerpos humanizados anti-cd19.
WO2005003169A3 (en) Modified antibody fab fragments
EP2275134A3 (fr) Utilisation d'anticorps optimisés en ADCC pour traiter les patients faibles répondeurs
WO2005115453A3 (en) Treatment of polychondritis and mononeuritis multiplex with anti-cd20 antibodies
WO2007114861A3 (en) Il-21 receptor antagonists
DE602005022315D1 (en) Taxol-immunoassay
WO2003072727A3 (en) EGFRvIII SPECIFIC MONOCLONAL ANTIBODY AND EGFRvIII RIBOZYMES AND USE TO DETECT, TREAT OR PREVENT EGFRvIII ASSOCIATED CANCER
WO2007003421A3 (en) Humanised antibodies specific for nogo-a and pharmaceutical uses thereof